Consensus Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Real-time Estimate Cboe BZX Other stock markets 10:19:37 06/05/2024 pm IST			5-day change	1st Jan Change
7.52 ^USD	-0.13%		+12.22%	+28.06%

27/02	North American Morning Briefing : Stock Futures -2-	DJ
26/02	Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	MT

Evolution of the average Target Price on Cogent Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a571ad39d1b78c59f5.8T6RNPkIS1f-Xq9VlhqNu-hlNWV6yB6S8XuYpvNPsVk.rn_6XLJ5HjCbC8IswW20zr9WYCwuq2bRrjT-yYMiyDLBdKgZm0wsMc0Q-g~fea574a27f4a6d3ad1d3c3f438b00381

Analyst Recommendations on Cogent Biosciences, Inc.

Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	26/02	MT
Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14	26/02	MT
Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating	23/02	MT
Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target	08/02	MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating	15/12	MT
Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20	11/12	MT
JPMorgan Chase Starts Coverage on Cogent Biosciences with Overweight Rating, $18 Price Target	08/12	MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $27 From $28, Keeps Buy Rating	08/23/08	MT
Baird Initiates Cogent Biosciences at Outperform With $20 Price Target	28/23/28	MT
Needham Adjusts Price Target on Cogent Biosciences to $23 From $24, Keeps Buy Rating	15/23/15	MT
Wedbush Adjusts Price Target on Cogent Biosciences to $20 From $19, Maintains Outperform Rating	14/23/14	MT
SVB Securities Adjusts Price Target on Cogent Biosciences to $20 From $18, Maintains Outperform Rating	05/23/05	MT
Needham Starts Cogent Biosciences With Buy Rating, Price Target is $24	14/22/14	MT
Guggenheim Adjusts Price Target on Cogent Biosciences to $24 From $22, Maintains Buy Rating	13/22/13	MT
Cogent Biosciences Says Bezuclastinib Shows Overall Response Rate of 73% in Advanced Systemic Mastocytosis Phase 2 Trial	12/22/12	MT
Wedbush Trims Cogent Biosciences' Price Target to $19 From $20, Keeps Outperform Rating	14/22/14	MT
Guggenheim Adjusts Cogent Biosciences Price Target to $22 From $18, Maintains Buy Rating	18/22/18	MT
Wedbush Adjusts Cogent Biosciences Price Target to $20 From $17, Maintains Outperform Rating	09/22/09	MT
SVB Financial Adjusts Cogent Biosciences Price Target to $20 From $15, Maintains Outperform Rating	08/22/08	MT
Guggenheim Starts Cogent Biosciences at Buy With $15 Price Target	28/22/28	MT
SVB Securities Adjusts Cogent Biosciences' Price Target to $15 from $14, Keeps Outperform Rating	13/22/13	MT
Wedbush Adjusts Price Target for Cogent Biosciences to $17 From $21, Maintains Outperform Rating	11/22/11	MT
Wedbush Adjusts Cogent Biosciences' Price Target to $21 From $19; Outperform Rating Kept	15/22/15	MT
COGENT BIOSCIENCES : HC Wainwright Starts Cogent Biosciences at Buy With $25 Price Target	11/21/11	MT
COGENT BIOSCIENCES : Wedbush Adjusts Cogent Biosciences PT to $19 From $24, Maintains Outperform Rating	16/21/16	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.53 USD

Average target price

17 USD

Spread / Average Target

+125.76%

High Price Target

26 USD

Spread / Highest target

+245.29%

Low Price Target

8 USD

Spread / Lowest Target

+6.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Cogent Biosciences, Inc.

Citigroup
Baird
Wedbush
HC Wainwright
JPMorgan Chase
Needham & Co.
SVB Securities LLC
Guggenheim
SVB Financial
Jefferies & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar